Results 51 to 60 of about 222,357 (321)
Journal of Medical Case Reports, 2022 Background Glioblastoma belongs to the most common and most aggressive tumor entity of the central nervous system with a poor prognosis of only few months.
Roopa Jayarama-Naidu, Evelyn Gallus
doaj +1 more source
Therapeutics and Clinical Risk Management, 2015 Individuals with glioblastoma are often characterized by older age, advanced neurologic manifestations at the primary stage, and unresectable tumors, and these factors are associated with poor treatment outcomes. Administration of bevacizumab (BV, Avastin(®)) promotes tumor regression and improves cerebral edema, and is expected to improve neurologic ...
openaire +5 more sources
Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells
Molecular Oncology, EarlyView.In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi +3 more
wiley +1 more source
CellsThe overall goal of this work was to assess the ability of Natural Killer cells to kill cultures of patient-derived glioblastoma cells. Herein we report impressive levels of NK-92 mediated killing of various patient-derived glioblastoma cultures observed
Jane Yu +7 more
doaj +1 more source
Gliosarcoma Transforming from Giant Cell Glioblastoma: A Case Report and Review of the Literature
Haseki Tıp Bülteni, 2019 Giant cell glioblastoma and gliosarcoma are rare histological variants of glioblastoma multiforme. These are WHO Grade IV astrocytic tumors. While giant cell glioblastoma can be seen at younger age, gliosarcoma typically presents at age 40-60 years ...
Elife Kımıloğlu +3 more
doaj +1 more source
Piezoelectric Barium Titanate Nanostimulators for the Treatment of Glioblastoma Multiforme [PDF]
Journal of Colloid and Interface Science, Volume 538, 7 March
2019, Pages 449-461, 2018 Major obstacles to the successful treatment of gliolastoma multiforme are mostly related to the acquired resistance to chemotherapy drugs and, after surgery, to the cancer recurrence in correspondence of residual microscopic foci. As innovative anticancer approach, low-intensity electric stimulation represents a physical treatment able to reduce ...
arxiv +1 more source
Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors
Molecular Oncology, EarlyView.Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi +6 more
wiley +1 more source
Semapimod sensitizes glioblastoma tumors to ionizing radiation by targeting microglia. [PDF]
PLoS ONE, 2014 Glioblastoma is the most malignant and lethal form of astrocytoma, with patients having a median survival time of approximately 15 months with current therapeutic modalities. It is therefore important to identify novel therapeutics.
Ian S Miller +7 more
doaj +1 more source
Neddylation in glioblastomas [PDF]
Neuro-Oncology, 2015 Protein degradation is a highly regulated process that is required for maintaining cellular homeostasis, and its deregulation is associated with development of a number of diseases including cancer. Neddylation is a posttranslational modification that involves conjugation of the ubiquitin-like protein NEDD8 (neural precursor cell expressed ...
Sheila Mansouri, Gelareh Zadeh
openaire +3 more sources
Molecular Oncology, EarlyView.The authors conducted a retrospective study of 94 patients with advanced cancer who underwent next‐generation sequencing (NGS) gene panel analysis and received targeted treatments when applicable. Results further support evidence indicating that molecular profiling provides clinical benefit.
Michaël Dang +3 more
wiley +1 more source